The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.

@article{Pafili2016ThePO,
  title={The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.},
  author={Kalliopi Pafili and Efstratios S Maltezos and N. Papanas},
  journal={Expert opinion on investigational drugs},
  year={2016},
  volume={25 10},
  pages={
          1133-52
        }
}
INTRODUCTION There is now an abundance of anti-diabetic agents. However, only few patients achieve glycemic targets. Moreover, current glucose-lowering agents mainly depend upon insulin secretion or function. Sodium glucose co-transporter type 2 (SGLT2) inhibitors present a novel glucose-lowering therapy, inducing glycosuria in an insulin-independent fashion. AREAS COVERED In this review, the authors discuss the key efficacy and safety data from phase II clinical trials in type 2 diabetes… CONTINUE READING
1
Twitter Mention

Topics from this paper.